Welcome to our dedicated page for Adia Nutrition news (Ticker: ADIA), a resource for investors and traders seeking the latest updates and insights on Adia Nutrition stock.
Adia Nutrition Inc. (OTCQB: ADIA) generates frequent news and updates centered on its work in regenerative medicine, stem cell therapies, and wellness-focused healthcare. Company announcements highlight developments across its Adia Med clinical platform, Adia Labs regenerative product division, and related health and wellness investments.
Recent news has focused on Adia Med of Winter Park’s Autism Spectrum Disorder (ASD) clinical study, a randomized interventional trial listed on ClinicalTrials.gov (NCT07304440). Releases describe IRB approval from BeyondBound, the study’s design comparing glutathione alone to glutathione combined with AdiaVita, and the launch of patient recruitment for approximately 100 children ages 3–12. These updates provide insight into Adia’s clinical research pipeline and its approach to combining antioxidants with umbilical cord blood-derived stem cells and exosomes.
News items also cover corporate and capital markets milestones, such as Adia’s uplisting to the OTCQB Venture Market, completion of SEC Rule 15c2‑11 requirements, and the filing of a Form 10 registration statement as a step toward full reporting status. Operational highlights include revenue growth commentary, expansion of the company’s sales infrastructure, partnerships that extend clinic oversight and marketing capabilities, and initiatives to broaden access to Adia Labs products and Adia Med services.
Additional coverage features partnerships and leadership appointments, including collaborations with media and marketing organizations and the addition of senior executives to support revenue generation and clinic network expansion. Visitors to this ADIA news page can review these releases to follow Adia Nutrition’s clinical studies, regenerative therapy offerings, clinic partnerships, and regulatory progress over time.
Adia Nutrition (OTCQB: ADIA) announced a strategic partnership with a leading Atlanta clinic to supply regenerative products for a new Autism Spectrum Disorder clinical study. The trial will enroll 100 participants, each receiving 3 infusions of AdiaVita (total 300 infusions); a single infusion is noted at about $8,000 as a price benchmark. Adia Med of Winter Park is separately recruiting for its own autism study starting May 2026. Adia Labs products are limited to research or IRB-approved studies and meet stated FDA quality and donor standards.
Adia Nutrition (OTCQB: ADIA) reported fiscal 2025 results and a strategic shift into regenerative medicine. Revenue rose to $700,508 from $6,380 in 2024, with gross profit of $191,670. The company recorded an operating loss of $366,492 and net loss of $395,464 and disclosed going-concern doubt.
Adia achieved full SEC reporting status in February 2026 and operates divisions Adia Med, Adia Labs, and Biolete while investing in R&D, clinical services, and infrastructure.
Adia Nutrition (OTCQB: ADIA) will host a live Zoom presentation tonight, March 24, 2026 at 6:00 PM EDT, with UCF CARD to explain an ongoing 24-month, IRB-approved clinical study (ClinicalTrials.gov ID: NCT07304440).
The trial is recruiting children ages 3–12 with autism and evaluates AdiaVita umbilical cord blood-derived stem cells and exosomes plus glutathione. Registration is free via Eventbrite and contact details are provided for enrollment and partnership inquiries.
Adia Nutrition (OTCQB: ADIA) appointed Amy Dalrymple, MSN, APRN, FNP-C, to lead its new Regenerative Aesthetics Division at Adia Med of Winter Park.
Dalrymple brings 11 years in aesthetic medicine; services launch with an open house on March 30, 2026 and patient treatments begin April 6, 2026.
Appointments, consultations, and licensing inquiries are available via adianutrition.com and adiamed.com or by phone at 321-788-0850.
Adia Med (OTCQB: ADIA) relaunched its website with ZenChange Marketing to centralize clinical research information, study summaries, enrollment details, and social media management. A highlighted initiative is the Autism Stem Cell Clinical Study (NCT07304440), a 24-month investigational trial with active recruitment and a one-time participation cost of $12,000.
The interventional phase is anticipated to begin in May 2026. The organization emphasizes investigational status, informed consent, medical oversight, and participant safety while using a patient-pay model without grants or government funding.
Adia Nutrition (OTCQB: ADIA) announced that subsidiary Adia Med submitted a final revised protocol to the Institutional Review Board on March 3, 2026, for a lower back pain study of AdiaVita.
The trial is a single-blind, placebo-controlled IV study randomizing ~100 participants with a three-month initial treatment and a crossover phase; patient-pay remains $5,000 per participant.
Adia Nutrition (OTCQB: ADIA) said its Adia Med Winter Park clinic is expanding into cosmetic services and is interviewing a Nurse Practitioner for hair growth and aesthetic procedures as of February 24, 2026. New offerings include microneedling and targeted hair-restoration treatments using Adia's high-concentration stem cell products such as AdiaVita (advertised as 100 million stem cells and 3.5 trillion exosomes per unit).
The clinic invites qualified candidates and potential licensing partners to contact Adia Med for roles, services, and strategic collaborations at the Winter Park location.
Adia Nutrition (OTCQB: ADIA) said subsidiary Adia Med submitted a second clinical study for IRB review on February 16, 2026, testing AdiaVita delivered intravenously for lower back pain. The single-blind, placebo-controlled trial will randomize about 100 participants and uses a three-month treatment then crossover design.
Participation is patient-pay at $5,000 per patient, with no extra cost for the crossover phase. Enrollment begins after IRB approval and ClinicalTrials.gov acceptance.
Adia Nutrition (OTCQB: ADIA) plans to launch four to five new clinical studies in 2026, expanding work with Adia Vita (umbilical cord blood-derived stem cells and exosomes).
Key initiatives include an IRB-approved Autism Spectrum Disorder (NCT07304440) expansion to include 13-year-olds and a new study evaluating Adia Vita in rheumatoid arthritis. The company is pursuing multi-site IRB approvals and partnerships to support nationwide research and continues recruiting for its 24-month ASD trial following BeyondBound IRB approval in late 2025.
Adia Nutrition (OTCQB: ADIA) announced its Form 10 registration statement became effective on February 3, 2026, transitioning the company to full SEC reporting under Section 12(g). As a fully reporting registrant, Adia will file audited Form 10-Ks, quarterly 10-Qs, 8-Ks, and other disclosures.
The company said it is accelerating preparations for a potential NASDAQ Capital Market uplisting, named Dr. Brian Browning lead physician, noted an IRB-approved autism stem cell study now open worldwide, and referenced broad operational expansion in 2025.